10.1097/HJH.0000000000000871 272 RamsayL
DaBroi MGMalvezziHPazCCFerrianiRANavarroPA
Knowing why this happens and how to minimize symptoms can help you stick with treatment and reach your goals
In the landmark SURMOUNT-1 trial, published in the New England Journal of Medicine, participants taking 15mg of tirzepatide lost an average of 20.9% of their body weight over 72 weeks
While both peptides share the common goal of increasing the bodys natural growth hormone (GH) production, they work through fundamentally different biological mechanisms, which affects their clinical applications, side effect profiles, and suitability for different patients
As the 3 mg liraglutide product is approved for chronic weight management, it seems reasonable for patients to continue therapy until they have lost 5 to 10% of their baseline body weight and potentially longer if there is evidence of further and/or durable weight loss associated with treatment